| 马宇航,彭永德.2型糖尿病降糖药物治疗进展[J].中国临床保健杂志,2020,23(4):437-445. |
| 2型糖尿病降糖药物治疗进展 |
| Development of drug therapy for type 2 diabetes mellitus |
| |
| DOI：10.3969/J.issn.1672-6790.2020.04.002 |
| 中文关键词: 糖尿病,2型 药物疗法 药理作用分子作用机制 |
| 英文关键词: Diabetes mellitus,type 2 Drug therapy Molecular mechanisms of pharmacological action 〖FL |
| 基金项目: |
|
| 摘要点击次数: 4992 |
| 全文下载次数: 7332 |
| 中文摘要: |
| 2型糖尿病(T2DM)是一种慢性疾病,是全球重要的公共卫生问题,也是患者致残、致死的主要原因。T2DM具有多重发病机制,因此糖尿病治疗应尽可能针对多种病因进行治疗,尽量逆转已知的病变,同时尽早预防和治疗糖尿病相关并发症。近些年,很多新型降糖药物不断涌现,与传统的降糖药物相比,前者更多兼顾了药物的简便性、安全性、有效性以及多靶点作用机制,同时也兼顾了心肾保护等作用,考虑了糖尿病并发症的获益因素。有些新型降糖药如胰高血糖素样肽1受体激动剂(GLP-1RA)和钠-葡萄糖协同转运蛋白2抑制剂(SGLT-2i)的治疗地位在多项指南中也得到了重要提升。本文系统地回顾了现有的降糖药物,并对目前的新型降糖药物作了详细的介绍。 |
| 英文摘要: |
| Type 2 diabetes mellitus (T2DM) is a chronic disease,an important public health problem in the world,and also the main cause of disability and death.T2DM has multiple pathogenesis,so the treatment of diabetes should focus on multiple mechanism,reverse the known pathophysiological changes,and prevent and treat diabetes complications.In recent years,many new hypoglycemic drugs are developed.Compared with traditional hypoglycemic drugs,new hypoglycemic drugs have the characteristics of simplicity,safety,effectiveness,multi-target mechanism,cardiorenal protection and other benefits for diabetic complications.Some new hypoglycemic drugs,such as glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium glucose co transporter 2 inhibitors (SGLT-2i),are also playing an important role in many guidelines.This paper reviews the existing hypoglycemic drugs and their targets,and introduces the new hypoglycemic drugs in detail. |
|
查看全文
|
| 关闭 |
|
|
|